Adalimumab News and Research

RSS
Adalimumab is an injectable prescription drug used to treat diseases of the immune system; it is marketed by Abbot as Humira. It is one of three drugs that work by inhibiting the potent inflammatory molecule tumor necrosis factor-alpha (TNF-alpha); the others are etanercept (Enbrel) and infliximab (Remicade). Like etanercept and infliximab, adalimumab is a large protein molecule made with recombinant DNA technology. Adalimumab is a monoclonal antibody of the IgG1 subtype that has been "humanized", meaning that all of its components are derived from human molecules.
Convenient new treatment option for rheumatoid arthritis sufferers offers patient freedom and control of disease

Convenient new treatment option for rheumatoid arthritis sufferers offers patient freedom and control of disease

REACT clinical trial provides valuable new insights for community gastroenterologists that benefit patients

REACT clinical trial provides valuable new insights for community gastroenterologists that benefit patients

Children newly diagnosed with Crohn's disease may benefit from biologic drugs

Children newly diagnosed with Crohn's disease may benefit from biologic drugs

AGA guidelines recommend anti-TNF-α biologic agents to induce remission in Crohn's disease patients

AGA guidelines recommend anti-TNF-α biologic agents to induce remission in Crohn's disease patients

Adalimumab may be viable treatment option for patients with refractory pediatric uveitis

Adalimumab may be viable treatment option for patients with refractory pediatric uveitis

AbbVie announces HUMIRA phase II study results for treating hidradenitis suppurativa

AbbVie announces HUMIRA phase II study results for treating hidradenitis suppurativa

Study describes lack of positive effects in drugs, long-term data and robust direct comparisons in RA

Study describes lack of positive effects in drugs, long-term data and robust direct comparisons in RA

AMPLE trial demonstrates similar safety profiles and efficacy between abatacept and adalimumab in RA

AMPLE trial demonstrates similar safety profiles and efficacy between abatacept and adalimumab in RA

Study demonstrates efficacy of ARASHI method at evaluating radiographic joint damage in RA

Study demonstrates efficacy of ARASHI method at evaluating radiographic joint damage in RA

Only one-fifth of RA patients had overall adherence rate to prescribed oral medications, study finds

Only one-fifth of RA patients had overall adherence rate to prescribed oral medications, study finds

Sanofi, Regeneron enroll patients in two sarilumab Phase 3 trials for treatment of RA

Sanofi, Regeneron enroll patients in two sarilumab Phase 3 trials for treatment of RA

Study: Biologic response modifying drugs can cause acute liver injury

Study: Biologic response modifying drugs can cause acute liver injury

Crohn’s permanent stoma rates plummet in post-biologic era

Crohn’s permanent stoma rates plummet in post-biologic era

Bone Medical announces initial findings from BN006 proof of concept RA study

Bone Medical announces initial findings from BN006 proof of concept RA study

Arthritis, rheumatism and total joint arthroplasty: an interview with Dr Ravi and Dr Hawker

Arthritis, rheumatism and total joint arthroplasty: an interview with Dr Ravi and Dr Hawker

Top-line results from AstraZeneca’s fostamatinib Phase IIb monotherapy study on RA

Top-line results from AstraZeneca’s fostamatinib Phase IIb monotherapy study on RA

Rheumatoid arthritis patients adhere to both adalimumab, etanercept

Rheumatoid arthritis patients adhere to both adalimumab, etanercept